MedTrace Logo

A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT06241898 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2025-09-26

No results posted yet for this study

Summary

The goal of this clinical trial is to test in patients with local advanced/metastatic solid tumors. the main questions it aims to answer are:

* to assess the safety and tolerability of BB-1709.
* to determine the maximum tolerated dose(MTD) and/or the PR2D of BB-1709

Conditions

Interventions

DRUG

BB-1709

Subjects participating in Phase Ia study may continue to receive study treatment as long as they continue to show clinical benefit as judged by the investigator, until disease progression or intolerable toxicity, withdrawal of consent, death, or termination of the study.

Sponsors & Collaborators

  • Bliss Biopharmaceutical (Hangzhou) Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2026-06-30
Completion
2026-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06241898 on ClinicalTrials.gov